Heiss W D, Kracht L, Grond M, Rudolf J, Bauer B, Wienhard K, Pawlik G
Max-Planck Institut für neurologische Forschung and Neurologische Universitätsklinik, Cologne, Germany.
Stroke. 2000 Feb;31(2):366-9. doi: 10.1161/01.str.31.2.366.
Central benzodiazepine receptor ligands, such as [(11)C]flumazenil (FMZ), are markers of neuronal integrity and therefore might be useful in the differentiation of functionally and morphologically damaged tissue early in ischemic stroke. We sought to assess the value of a benzodiazepine receptor ligand for the early identification of irreversible ischemic damage to cortical areas that cannot benefit from reperfusion.
Eleven patients (7 male, 4 female, aged 52 to 75 years) with acute, hemispheric ischemic stroke were treated with alteplase (recombinant tissue plasminogen activator; 0.9 mg/kg according to National Institute of Neurological Disorders and Stroke protocol) within 3 hours of onset of symptoms. At the beginning of thrombolysis, cortical cerebral blood flow ([(15)O]H(2)O) and FMZ binding were assessed by positron emission tomography (PET). Those early PET findings were related to the change in neurological deficit (National Institutes of Health Stroke Scale) and to the extent of cortical damage on MRI or CT 3 weeks after the stroke.
Hypoperfusion was observed in all cases, and in 8 patients the values were below critical thresholds estimated at 12 mL/100 g per minute, comprising 1 to 174 cm(3) of cortical tissue. Substantial reperfusion was seen in most of these regions 24 hours after thrombolysis. In 4 cases, distinct areas of decreased FMZ binding were detected. Those patients suffered permanent lesions in cortical areas corresponding to their FMZ defects (112 versus 146, 3 versus 3, 2 versus 1, and 128 versus 136 cm(3)). In the other patients no morphological defects were detected on MRI or CT, although blood flow was critically decreased in areas ranging in size up to 78 cm(3) before thrombolysis.
These findings suggest that imaging of benzodiazepine receptors by FMZ PET distinguishes between irreversibly damaged and viable penumbra tissue early after acute stroke.
中枢苯二氮䓬受体配体,如[(11)C]氟马西尼(FMZ),是神经元完整性的标志物,因此可能有助于在缺血性卒中早期区分功能和形态受损的组织。我们试图评估一种苯二氮䓬受体配体对于早期识别无法从再灌注中获益的皮质区域不可逆缺血损伤的价值。
11例急性半球缺血性卒中患者(7例男性,4例女性,年龄52至75岁)在症状发作3小时内接受阿替普酶(重组组织型纤溶酶原激活剂;按照美国国立神经病学、语言障碍和卒中研究所方案为0.9mg/kg)治疗。在溶栓开始时,通过正电子发射断层扫描(PET)评估皮质脑血流量([(15)O]H₂O)和FMZ结合情况。这些早期PET结果与神经功能缺损的变化(美国国立卫生研究院卒中量表)以及卒中后3周MRI或CT上皮质损伤的程度相关。
所有病例均观察到灌注不足,8例患者的值低于估计的每分钟12mL/100g的临界阈值,累及1至174cm³的皮质组织。溶栓后24小时,这些区域大多出现大量再灌注。4例患者检测到FMZ结合明显降低的区域。这些患者在与FMZ缺陷相对应的皮质区域出现永久性病变(分别为112对146、3对3、2对1和128对136cm³)。其他患者在MRI或CT上未检测到形态学缺陷,尽管溶栓前血流量严重降低的区域最大达78cm³。
这些发现表明,通过FMZ PET对苯二氮䓬受体进行成像可在急性卒中后早期区分不可逆损伤的组织和存活的半暗带组织。